Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06985576) titled 'Long-term Study to Evaluate Safety and Persistence of GF-CART01' on May 15.

Study Type: Observational

Primary Sponsor: GenomeFrontier Therapeutics TW Co., Ltd.

Condition: DLBCL - Diffuse Large B Cell Lymphoma Follicular Lymphoma (FL) Primary Mediastinal Large B-Cell Lymphoma High Grade B Cell Lymphoma

Recruitment Status: Not recruiting

Date of First Enrollment: May 2026

Target Sample Size: 18

Countries of Recruitment: Taiwan

To know more, visit https://clinicaltrials.gov/ct2/show/NCT06985576

Disclaimer: Curated by HT Syndication....